Efficacy of Postoperative Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-analysis

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2018 Jun 22

PMID 29927075

Citations 19

Authors

Peiliang Zhao

Wanpu Yan

Hao Fu

Yao Lin

Ke-Neng Chen

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer and most clinically curable patients are diagnosed with locally advanced disease. While the efficacy of preoperative treatment is relatively clear and well characterized, the effect of postoperative treatment, especially postoperative chemotherapy, remains controversial, and its role in the treatment strategy is obscure. We conducted an updated meta-analysis to include recent developments.

Methods: A comprehensive search in the PubMed, Embase, and Cochrane databases was performed to identify studies published from the inception of each database to February 2018. The overall survival (OS) and disease-free survival (DFS) rates of patients treated with and without postoperative chemotherapy were analyzed and compared. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the associations between postoperative chemotherapy and patient survival. Potential publication bias was assessed using Egger's line regression test.

Results: A total of nine studies, including three randomized controlled trials and six retrospective studies, were retrieved from the databases, comprising a total of 1684 cases. The results showed that postoperative chemotherapy could improve OS (HR 0.78, 95% CI 0.66-0.91; P = 0.002) and DFS (HR 0.72, 95% CI 0.6-0.86; P < 0.001).

Conclusions: The current meta-analysis supports postoperative chemotherapy as an independent favorable prognostic factor for ESCC, which could improve both OS and DFS.

Citing Articles

Postoperative Adjuvant Therapy Benefits Non-pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real-World Study.

Liu D, Liu A, Guo L, Li Y, Li Y, Chi Y Thorac Cancer. 2025; 16(4):e70021.

PMID: 39988453 PMC: 11847616. DOI: 10.1111/1759-7714.70021.

Postoperative adjuvant immunotherapy for pathological stage II-IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates.

Xie X, Zhang H, He H, Wu B, Chen Y, Lin W Front Med (Lausanne). 2024; 11:1517001.

PMID: 39735702 PMC: 11671493. DOI: 10.3389/fmed.2024.1517001.

Prognostic value of the cholesterol-dependent nutritional prognostic index in patients receiving adjuvant chemotherapy after radical esophageal cancer treatment.

Long Y, Shi R Eur J Med Res. 2024; 29(1):550.

PMID: 39548556 PMC: 11568555. DOI: 10.1186/s40001-024-02136-4.

Optimal extent of lymphadenectomy improves prognosis and guides adjuvant chemotherapy in esophageal cancer: A propensity score-matched analysis.

Tang J, Huang S, Chen Q, Wu H, Qiao G World J Gastrointest Surg. 2024; 16(6):1537-1547.

PMID: 38983355 PMC: 11230019. DOI: 10.4240/wjgs.v16.i6.1537.

PET/CT deep learning prognosis for treatment decision support in esophageal squamous cell carcinoma.

Song J, Zhang J, Liu G, Guo Z, Liao H, Feng W Insights Imaging. 2024; 15(1):161.

PMID: 38913225 PMC: 11196479. DOI: 10.1186/s13244-024-01737-1.

References

Saunders J, Bowman C, Reece-Smith A, Pang V, Dorrington M, Mumtaz E . The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. J Surg Oncol. 2017; 115(7):821-829. DOI: 10.1002/jso.24601. View

Pasquer A, Gronnier C, Renaud F, Duhamel A, Thereaux J, Carrere N . Impact of Adjuvant Chemotherapy on Patients with Lymph Node-Positive Esophageal Cancer who are primarily Treated with Surgery. Ann Surg Oncol. 2015; 22 Suppl 3:S1340-9. DOI: 10.1245/s10434-015-4658-1. View

Lee J, Lee K, Im Y, Kang W, Park K, Kim K . Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2005; 80(4):1170-5. DOI: 10.1016/j.athoracsur.2005.03.058. View

Malthaner R, Wong R, Spithoff K . Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. Clin Oncol (R Coll Radiol). 2010; 22(4):250-6. DOI: 10.1016/j.clon.2010.02.005. View

Saeed N, Mellon E, Meredith K, Hoffe S, Shridhar R, Frakes J . Adjuvant chemotherapy and outcomes in esophageal carcinoma. J Gastrointest Oncol. 2017; 8(5):816-824. PMC: 5674263. DOI: 10.21037/jgo.2017.07.10. View

Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K . Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?. J Surg Oncol. 2014; 110(7):864-8. DOI: 10.1002/jso.23716. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

Hashiguchi T, Nasu M, Hashimoto T, Kuniyasu T, Inoue H, Sakai N . Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer. Mol Clin Oncol. 2014; 2(5):719-724. PMC: 4106741. DOI: 10.3892/mco.2014.320. View

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T . Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol. 2003; 21(24):4592-6. DOI: 10.1200/JCO.2003.12.095. View

10.

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H . A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2011; 19(1):68-74. DOI: 10.1245/s10434-011-2049-9. View

11.

Heroor A, Fujita H, Sueyoshi S, Tanaka T, Toh U, Mine T . Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg. 2003; 20(3):229-35; discussion 236-7. DOI: 10.1159/000070390. View

12.

Allum W, Blazeby J, Griffin S, Cunningham D, Jankowski J, Wong R . Guidelines for the management of oesophageal and gastric cancer. Gut. 2011; 60(11):1449-72. DOI: 10.1136/gut.2010.228254. View

13.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

14.

Enzinger P, Mayer R . Esophageal cancer. N Engl J Med. 2003; 349(23):2241-52. DOI: 10.1056/NEJMra035010. View

15.

Zhang J, Chen H, Zhang Y, Xiang J . Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res. 2008; 36(5):875-82. DOI: 10.1177/147323000803600502. View

16.

Little A, Lerut A, Harpole D, Hofstetter W, Mitchell J, Altorki N . The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. Ann Thorac Surg. 2014; 98(5):1880-5. DOI: 10.1016/j.athoracsur.2014.07.069. View

17.

. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319):1727-33. DOI: 10.1016/S0140-6736(02)08651-8. View

18.

Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D . Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v50-v57. DOI: 10.1093/annonc/mdw329. View

19.

Pouliquen X, Levard H, Hay J, McGee K, Fingerhut A . 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg. 1996; 223(2):127-33. PMC: 1235087. DOI: 10.1097/00000658-199602000-00003. View

20.

van Hagen P, Hulshof M, van Lanschot J, Steyerberg E, van Berge Henegouwen M, Wijnhoven B . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-84. DOI: 10.1056/NEJMoa1112088. View